Please assess the completion status of the following clinical trial:

Trial Title: Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of recurrent or metastatic colorectal carcinoma previously resected within 12 weeks of study entry~  * Surgical resection combined with radiofrequency ablation allowed~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Hemoglobin at least 8.0 g/dL~* Absolute neutrophil count at least 1,000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Partial thromboplastin time (PTT)/prothrombin time (PT) no greater than 120% of control (except in therapeutically anticoagulated nonrelated medical conditions \[e.g., atrial fibrillation\])~* Total bilirubin no greater than 2.0 mg/dL (direct bilirubin no greater than 1.0 mg/dL for patients with Gilbert's syndrome)~* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than 2.5 times normal~* No history of hepatic cirrhosis~* No concurrent hepatic dysfunction~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* No severe congestive heart failure or active ischemic heart disease~* No active clots within 1 year before diagnosis OR must be receiving concurrent treatment with anticoagulant (e.g., low molecular weight heparin or equivalent agent)~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use 1 highly effective method of contraception AND 1 additional effective method of contraception for least 4 weeks before, during, and for at least 4 weeks after study participation~* No history of severe hypothyroidism~* No history of seizures~* No significant history of other medical problems that would preclude surgery~* No peripheral neuropathy greater than grade 1, except localized neuropathy due to a mechanical cause or trauma~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior biologic therapy~Chemotherapy:~* At least 4 weeks since prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 4 weeks since prior radiotherapy~Surgery:~* See Disease Characteristics~Other:~* See Cardiovascular~* No concurrent sedating drugs that cannot be reduced to a minimal level~* No concurrent sedating recreational drugs or alcohol~* No concurrent antiseizure medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 - Thalidomide once daily (Type: EXPERIMENTAL): Patients receive oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
- Arm 2 - Placebo once daily (Type: PLACEBO_COMPARATOR): Patients receive oral placebo once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).